Pancreatic cancer is cancer that forms in the cells of the pancreas. 3d illustration
getty
Pancreatic cancer is one of the deadliest cancers because the protein driving it sits deep inside the cell, out of reach of most modern medicines. A new experimental treatment takes a different path. Instead of trying to block the harmful protein from the outside, it sneaks an antibody into the cell and pulls the protein out. In lab studies and animal models, this strategy slowed cancer growth, shrank tumors, and largely spared the healthy form of the same protein.
At the heart of more than 90 percent of pancreatic cancers is a single gene that acts like an on-off switch for cell growth. When it picks up a small spelling change, the switch jams in the “on” position, causing cells to multiply without stopping. Similar mutations also drive a large share of colon and lung cancers, making this gene one of the biggest targets in cancer medicine. Yet for decades, no drug could touch it.
The new approach uses tiny carrier particles to ferry antibodies inside the cell. Once there, the antibody finds the mutant protein and marks it for removal. The strategy joins two strengths in a single treatment: the precision of an antibody and a delivery system small enough to slip through the cell membrane.
Antibodies are Y-shaped proteins the body makes to lock onto a single target. Over the past three decades, they have changed treatment for many cancers, autoimmune diseases, and viral infections.
The catch is that antibodies are large. They work outside the cell, where they can grab proteins on the cell surface or floating in the blood. Many cancer drivers, like the KRAS gene (Kirsten rat sarcoma viral oncogene homolog), hide deep inside of the cell, behind a membrane that antibodies cannot cross. That has placed some of the most important cancer-driving proteins off limits to this class of medicine.
The new platform is designed to solve that problem. The antibody rides inside a protective particle that crosses the cell membrane, then unloads its cargo once it is inside. Because the system relies on antibodies for targeting, swapping in a different antibody could allow the same delivery method to be adapted for other diseases.
The challenge is ensuring the antibody recognizes only the mutant version of the gene. Healthy cells still need the normal KRAS gene to function. A treatment that hits both would cause damage beyond the tumor. The antibody used in this study was designed to lock onto the mutated form and ignore the healthy one. That selectivity is crucial because many cancer treatments often damage healthy tissue alongside tumors, leading to the side effects patients often fear.
In cancer cells carrying the mutant gene, the treatment cleared out the harmful protein. When mutant and normal cancer cells were studied together, only the mutant cells stopped growing. Their healthy neighbors continued growing as usual.
The results extended beyond the laboratory dish. In mice carrying human pancreatic tumors, repeated injections caused tumors to shrink, and some became almost impossible to find on scans by the end of the study. The animals maintained a stable weight, blood tests remained normal, and the major organs showed no signs of damage.
The findings arrive as interest grows in a new generation of medicines designed to target cancers driven by mutations in key signaling genes. One in development, Daraxonrasib, has shown promise in pancreatic cancer trials. It works by gripping the mutant protein and blocking the growth signal it sends.
The new approach takes a different step. Rather than keeping the harmful protein under control, the antibody causes the cell to remove it altogether. That distinction may matter for forms of the gene that existing drugs cannot easily target, as well as for tumors that eventually learn to evade treatment.
The same delivery system, loaded with a different antibody, also lowered levels of a protein tied to a brain disease in early tests. That finding hints at broader possibilities. Any disease driven by a harmful protein trapped inside the cell, from certain cancers to some forms of dementia, could one day become a target.
Much work remains before patients can be treated with this new platform. The current findings come from laboratory studies and mice, and human trials will need to show the same benefits hold up in people. Still, the direction is clear. The next frontier of targeted medicine may be removing disease-causing proteins rather than merely suppressing their activity.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。